Journey Colab is unlocking the science of psychedelics to build a new model of addiction care combining the potential of neuroplasticity-promoting therapeutics with psychotherapy and community support. Our lead compound is synthetic Mescaline HCl for patients with alcohol use disorder (AUD), who are in desperate need of durable remission from this chronic, relapsing condition. Through our unique stakeholder structure, we have built an experienced team dedicated to our mission of creating scientifically rigorous and clinically validated treatments and improving equitable access to care.
Location: United States, California, San Francisco
Member count: 1-10
Total raised: $15.707959M
Founded date: 2020
Investors 1
| Date | Name | Website |
| - | MBX Capita... | mbxcapital... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 01.11.2021 | - | $15.707959... | - | - |
Mentions in press and media 5
| Date | Title | Description | Source |
| 19.02.2023 | ChatGPT creator Sam Altman has invested in dozens of compani... | Sam Altman, CEO of OpenAI, has invested in scores of companies over the years. Kevin Dietsch/Getty I... | businessin... |
| 25.07.2022 | Working with Indigenous allies is the ethical way to develop... | Psychedelic medicine is having a moment of tremendous growth and innovation as researchers rediscove... | statnews.c... |
| 26.04.2022 | Mental Health Startup Journey Colab Aims To Develop Mescalin... | Alcohol use disorder (AUD) has increased during the Covid-19 pandemic Conventional therapies for... | forbes.com... |
| 07.09.2021 | Journey Colab scores $12M to move psychedelics-based addicti... | Psychedelics-focused biotech Journey Colab bagged $12 million to start its first human trial in 2022... | fiercebiot... |
| 07.09.2021 | Journey Colab scores $12M to move psychedelics-based addicti... | Psychedelics-focused biotech Journey Colab bagged $12 million to start its first human trial in 2022... | fiercebiot... |